Therapeutic Solutions International, Inc. announced the successful first treatment of a patient with FloraStilbene?, a patent pending formulation of the abortion pill?s active ingredient, RU486, and pterostilbene. The Company has been utilizing pterostilbene, a naturally occurring analog of resveratrol, found in blueberries, for the treatment of cancer and immune modulation for several years, including being granted a patent on synergies with conventional immunotherapies. In May of this year, Res Nova signed a collaborative agreement with compounding pharmacy Cure Stat Rx for developing a compounded formulation of FloraStilbene?.

FloraStilbene? has previously been shown to enhance immunotherapy of various tumors, as well as chemotherapy efficacy. In addition to Res Nova, Therapeutic Solutions International has multiple subsidiaries including Campbell Neurosciences, focused on the identification of suicidal propensities using a proprietary test and various interventions; Breath Biologics, which is in discussions with the FDA for its filed Phase I/II trial in COPD; CTE Biologics, which is advancing its clinical stage technology for treating Chronic Traumatic Encephalopathy; and VasoSome Vascular, which is in preclinical development of mesenchymal stem cell derived exosomes for treatment of aortic aneurysms.